Modeling‐Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial-Reference-Cited by-同舟云学术

Modeling‐Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial

Published:2021-11-19 Issue:1 Volume:37 Page:36-40
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J of Bone & Mineral Res

Author:

Eriksen Erik F¹²^ORCID,Chapurlat Roland³^ORCID,Boyce Rogely Waite⁴,Shi Yifei⁴,Brown Jacques P⁵,Horlait Stéphane⁶,Betah Donald⁴,Libanati Cesar⁷^ORCID,Chavassieux Pascale³^ORCID

Affiliation:

1. Institute of Clinical Dentistry, University of Oslo Oslo Norway

2. Spesialistsenteret Pilestredet Park Oslo Norway

3. INSERM UMR 1033 Université de Lyon, Hospices Civils de Lyon Lyon France

4. Amgen Inc Thousand Oaks CA USA

5. CHU de Québec Research Centre and Laval University Quebec City Canada

6. Amgen Boulogne‐Billancourt France

7. UCB Pharma Brussels Belgium

Funder

Amgen

Astellas Pharma US

UCB Pharma

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4457

Reference20 articles.

1. Romosozumab blocks the binding of sclerostin to the two key Wnt signaling co‐receptors, LRP5 and LRP6, but not to LRP4;Gong J;J Bone Miner Res.,2016

2. Romosozumab Treatment in Postmenopausal Women with Osteoporosis

3. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

4. Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

5. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw;Bone;2024-10

2. Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis;Journal of Orthopaedic Translation;2024-09

3. Recommendations for the optimal use of bone forming agents in osteoporosis;Aging Clinical and Experimental Research;2024-08-09

4. Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis;Osteoporosis International;2024-08-09

5. The potential effect of romosozumab on perioperative management for instrumentation surgery;JOR SPINE;2024-08-05